Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘Multiple Myeloma’

Does a Gaudy Night for GSK stand up under scrutiny?

Many moons ago the famous English writer Dorothy L. Sawyers wrote a series of novels about an aristocratic amateur sleuth called Lord Peter Wimsey.

When Wimsey attended the Gaudy dinner at Harriet Vane’s Oxford women’s college, the last thing he expected was to get caught up in a murder mystery.

Similarly, we might well wonder if the FDA will be surprised to see GSK, the sponsor of belantamab mafodotin, show up with a re-submission filing in multiple myeloma in an earlier setting several years on, especially since the toxicity profile hasn’t changed.  

In our latest data takedown we explore whether the findings hold water or not, including some expert opinions on the DREAMM-7 readout…

 

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

The guardian of the genome

Cambridge from Bay Bay Boston

Back Bay Boston

With the TARGETS meeting ending and ESMO soon to be starting up, I wanted to offer up a change of pace completely by highlighting some important new cell therapy research presented at the AACR Tumour Immunology and Immunotherapy meeting in Boston.

The CAR-T cell therapy space has certainly seen a lot of developments this year since we wrote about what was coming down the pike in February and here we are in the fourth quarter and the researchers in this niche continue to execute.

I suspect a lot of folks dismissed the first round of gene editing attempts for various reasons without really thinking deeply about why this might be the case and how the issues can be overcome.

This is not the case for the folks at the top of their game – they don’t give up, they go away and find out why things don’t work as expected, how we can overcome them, and importantly, improve on clinical trial execution…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Adding up the evidence

Is the emerging early stage myeloma landscape as bleak as Titan in Clydebank?

For years we have seen much of the therapeutic research in multiple myeloma concentrated on three main categories:

  • Proteasome inhibitors
  • IMiDs
  • Anti-CD38 antibodies

Then came a raft of anti- BCMA and GPRC5D targeted approaches in various forms, but what else should we be looking out for?

It turns out there’s quite a few contenders of interest – we cover some of them in our latest look at early stage compounds to watch out for…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Taking Myeloma by the Horns

The recent failure of the British Air Traffic Control System brought home to many the importance of flight plans and how easily and suddenly things can change.

Knowing the direction and waypoints a journey will take, allows travel to be co-ordinated across countries, as well as in combination with others.

The same idea applies to complex diseases such as multiple myeloma where we see treatment regimens evolve as new therapeutic modalities such as CAR-T cells or bispecific T cell engagers come to market and new clinical trial data is published.

Highland cows with horns are a fearsome lot!

With a raft of new data coming out post-pandemic, experts are starting to piece together new treatment plans and thoughts about where the field is going.

BSB will be at ASH23 in San Diego this year, so consider this post our first preview of some of the discussions and challenges we expect to hear about in multiple myeloma.

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Diet as a drug

We have heard much over the last decade or so about the impact of the microbiome on responses to hematopoeitic stem cell transplant (HSCT) and checkpoint blockade, but what about other immunotherapies such as CAR-T cells?

This could well be one of the unexpected X factors accounting for some of the differences in outcomes seen in clinical trials in this niche.

Increasingly, scientists and physicians are starting to see how we really might be what we eat as well as how diet might impact response to therapeutic intervention.

How then should we go about learning more about this issue and – and just as importantly – figuring out the next steps to improve function ahead of such treatment in order to maximise the survival outcomes for patients undergoing stem cell or CAR-T cell therapies?

To learn more about progress, we interviewed one of the pioneers in this field to see what he had to say…

To continue reading our latest highlights on oncology new product development, including expert commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Aspiring to new heights – and new modalities

With several important conferences coming up over the next 4-6 weeks, this is a good time to focus on an emerging modality.

This is an area which is slowly starting to see more interest from various biotech and pharma companies and yet the number of permuations and formats involved to optimise performance may well stymy rapid progress.

The big question I think for many of us is will they add to and go beyond what we have already or will they simply be another way of doing the same thing?

In this latest review of some important data we explore what’s what and what’s not in the context of the current and emerging landscape…

BSB subscribers can read our latest commentary – you can either log-in or click to access.

This content is restricted to subscribers

Challenges and opportunities with CAR-T cell therapies

Are we putting the cart before the horse – yea or neigh?

We’ve been following and writing about the CAR-T cell therapy space for over a decade now, with plenty of trials and tribulations along the way for both products and companies alike.

With the fanfare around the latest Penn data on Friday, we’re going to take a slightly different approach from the lay media and explore some of the ins and outs around the big strategic picture.

We’ll also be looking at some new data on multiple myeloma and CAR-T cell therapies. The latter are seeing the emergence of some interesting early studies of late…

BSB subscribers can read our latest commentary – you can either log-in or click to access.

This content is restricted to subscribers

Can a monoDAC hit the groove against IMiDs and CELMoDs?

The groovy C4T Office

As we continue our in-depth post AACR21 coverage, it’s time for part two in the protein degradation series with a look at C4 Therapeutics and what we can learn from their preclinical data presentation of CFT7455, where they aim to selectively destroy disease-causing proteins in multiple myeloma and lymphomas through degradation of IKZF1/3.

Also included is the second half of an interview with their charismatic CSO, Dr Stew Fisher where we discuss degraders, glues, IMiDs and CELMoDs…

To learn more about our ongoing post AACR21 meeting analysis and expert interviews to get a heads up on key oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

The King of Kings

A bold move?

Over the last couple of years we have been quietly interviewing the various biotech and pharma players in the protein degradation niche and exploring their numerous approaches and pipelines.

In the latest company interview, we take look at C4 Therapeutics (C4T), who are a relatively young company with preclinical data at AACR next month, plus their first clinical trial opening imminently, both excellent achievements in a relatively short space of time.

So what are C4T about and where do they seem themselves positioned? What are their goals and what should we be expecting to see/hear from them?  Do they have a shot at achieving their lofty aims?

To find out drop in and catch up on our latest CSO interview…

To learn more about C4 Therapeutics and get a heads up on our latest oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Strategic direction and future impacts in multiple myeloma

Shining a light on hidden gems in the myeloma niche

If we want to go beyond the proteasome inhibitors, IMiDs and anti-CD38 antibodies in multiple myeloma, there are plenty of emerging candidates these days.

This is excellent news, but how will it all fit together, and which gems were under-rated at the recent ASH meeting?

The latter may catch a few people by surprise when the clinical aspects are considered in the totality of what needs to be done and in which patient subsets.

We discuss near and medium term aspects, which may have a lasting impact and also talk about why they matter.

To find out, the final part of our myeloma mini-series offers an engaging and thoughtful fireside chat with a global thought leader in this niche…

To learn more from our oncology analysis and get a heads up on the latest insights and analysis pertaining to the multiple myeloma landscape, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!